Fatemeh Malekinejad

Fatemeh Malekinejad

Auto-generated profile, based on publicly available information

Fatemeh Malekinejad

Student Research Committee Tabriz University of Medical Sciences Tabriz Iran

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MOMobina Oladghaffari
Mobina Oladghaffari
HBHeliya Bandehagh
Heliya Bandehagh
FMFatemeh Malekinejad
Fatemeh Malekinejad
SFShahrzad Fakhkhari
Shahrzad Fakhkhari
NKNarges Koohi
Narges Koohi
ANAmirreza Naseri
Amirreza Naseri
Multiple sclerosis (MS) is still under investigation for its pathogenesis. This study explores the relationship between the key circadian rhythm regulators

22 September 2026 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
RKRasa Khosrofar
Rasa Khosrofar
FZFarshad Zare
Farshad Zare
SEShakiba Eftekhar
Shakiba Eftekhar
PFPouria Fathalipour
Pouria Fathalipour
AGAmir Gisouei
Amir Gisouei
MNMehrdad Nourizadeh
Mehrdad Nourizadeh
Autoimmune diseases arise from loss of immunological tolerance through interactions among genetic susceptibility, environmental exposures, immune-regulator

10 August 2026 in Veterinary Medicine and Science
Verified
Journal Article
Open access
KSKianoush Saberi
Kianoush Saberi
RARosull Saadoon Abbood
Rosull Saadoon Abbood
SASarah F. Al‐Taie
Sarah F. Al‐Taie
ASAseel Smerat
Aseel Smerat
AMAbdullaev Makhmudjon Mukhamedovich
Abdullaev Makhmudjon Mukhamedovich
RAReza Akhavan‐Sigari
Reza Akhavan‐Sigari
Background: Artificial intelligence (AI) is increasingly explored in veterinary neurology for pattern recognition, prediction and clinical decision support, with relevance to comparative and translational neuroscience. Objectives: This review examines AI applications in veterinary neurology, compares them with human neurology and evaluates cross‐species technology transfer within a One Health framework. Methods: A narrative review synthesized evidence across AI domains in veterinary neurology, including neuroimaging and radiomics, electrophysiology and seizure detection or forecasting, gait and pain assessment, morphometric biomarker discovery, prognostic modelling and laboratory diagnostic tools. Human studies were considered to identify translational opportunities, methodological challenges and the value of transfer learning and domain adaptation. Results: Available evidence suggests that AI holds promise for pattern recognition, prediction and decision support in veterinary neurology. Reported applications include canine brain tumour classification, spinal lesion grading, seizure monitoring and quantitative gait analysis, with encouraging performance. However, most applications remain proof‐of‐concept. The evidence base is dominated by retrospective single‐centre studies with small samples, heterogeneous protocols and limited prospective or external validation. Model calibration, uncertainty reporting and clinically relevant error trade‐offs are often insufficiently addressed. Transfer learning and domain adaptation may help overcome limited veterinary datasets, while naturally occurring neurological disease in dogs may also support refinement of human AI systems. Conclusions: AI in veterinary neurology is a promising but early field. Future progress will require multi‐centre collaboration, standardized data practices, explainable and ethically governed models and stronger One Health partnerships to support safe translation.

1 January 2026 in Parkinson's Disease
Verified
Journal Article
Open access
SPSina Pakkhesal
Sina Pakkhesal
SLSeyedyashar Pourebrahimian Leilabadi
Seyedyashar Pourebrahimian Leilabadi
SHSina Hamzehzadeh
Sina Hamzehzadeh
FZFarshad Zare
Farshad Zare
EGElnaz Gholipour-Khalili
Elnaz Gholipour-Khalili
ANAmirreza Naseri
Amirreza Naseri
Parkinson’s disease (PD) is a neurodegenerative condition, and its rising prevalence necessitates the urgent need to identify modifiable risk factors. Air pollution, a pervasive and also escalating public health problem, has emerged as a potential contributor to the incidence and progression of PD. As urbanization and industrialization continue to exacerbate global air pollution levels, understanding the relationship between airborne toxicants and PD is a pressing scientific and public health priority. In this review, we critically discuss the current epidemiological evidence and the cellular and molecular mechanisms underlying air pollution‐induced neurodegeneration in PD. Clinical studies associate long‐term interaction with pollutants such as nitrogen oxides, particulate matter, and ozone with increased PD risk. Evidence also suggests that air pollution worsens PD prognosis. Mechanistically, air pollution is hypothesized to contribute to PD pathogenesis through gut microbiome alternations, oxidative stress, and neuroinflammatory pathways, as well as promoting α‐synuclein aggregation.

28 October 2026 in Discover Oncology
Verified
Journal Article
Open access
FMFatemeh Malekinejad
Fatemeh Malekinejad
KAKimia Azami
Kimia Azami
RARonak Ahmadi
Ronak Ahmadi
RNRazieh Nabizadeh
Razieh Nabizadeh
MNMehrdad Nourizadeh
Mehrdad Nourizadeh